CRISPR Ther­a­peu­tics, Case­bia ink AAV deal with Stride­Bio; Puma gets an Ad­Comm date; Mer­ri­mack names new R&D chief

→ CRISPR Ther­a­peu­tics $CR­SP and Case­bia Ther­a­peu­tics, a joint-ven­ture es­tab­lished by CRISPR Ther­a­peu­tics and Bay­er AG, have inked a col­lab­o­ra­tion agree­ment with Stride­Bio to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER